Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALXN
Previous Symbol
CUSIP01535110
Phone475-230-2596
Debt
Debt-to-Equity Ratio0.32
Current Ratio3.16
Quick Ratio2.74
Price-To-Earnings
Trailing P/E Ratio21.79
Forward P/E Ratio16.49
P/E Growth0.99
Sales & Book Value
Annual Sales$3.55 billion
Price / Sales7.06
Cash Flow$7.8677 per share
Price / Cash Flow14.29
Book Value$39.81 per share
Price / Book2.82
Profitability
EPS (Most Recent Fiscal Year)$5.16
Net Income$443.30 million
Net Margins3.90%
Return on Equity16.60%
Return on Assets10.90%
Miscellaneous
Employees2,525
Outstanding Shares223,100,000
Market Cap$25.62 billion
OptionableOptionable
Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions
What is Alexion Pharmaceuticals' stock symbol?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."
How will Alexion Pharmaceuticals' stock buyback program work?
Alexion Pharmaceuticals announced that its board has initiated a share repurchase program on Sunday, April 9th 2017, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 3.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board believes its shares are undervalued.
How were Alexion Pharmaceuticals' earnings last quarter?
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted its quarterly earnings data on Wednesday, October, 24th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.74 by $0.28. The biopharmaceutical company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The company's revenue was up 19.5% on a year-over-year basis. During the same period last year, the company posted $1.44 earnings per share. View Alexion Pharmaceuticals' Earnings History.
When is Alexion Pharmaceuticals' next earnings date?
What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?
Alexion Pharmaceuticals updated its FY18 earnings guidance on Wednesday, October, 24th. The company provided EPS guidance of $7.45-7.60 for the period, compared to the Thomson Reuters consensus estimate of $7.24. The company issued revenue guidance of $4.02-4.05 billion, compared to the consensus revenue estimate of $4.04 billion.Alexion Pharmaceuticals also updated its FY 2018 guidance to $7.45-7.60 EPS.
What price target have analysts set for ALXN?
18 brokerages have issued 1-year target prices for Alexion Pharmaceuticals' stock. Their forecasts range from $123.00 to $190.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $163.1176 in the next year. This suggests a possible upside of 45.1% from the stock's current price. View Analyst Price Targets for Alexion Pharmaceuticals.
What is the consensus analysts' recommendation for Alexion Pharmaceuticals?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 2 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alexion Pharmaceuticals.
Has Alexion Pharmaceuticals been receiving favorable news coverage?
News coverage about ALXN stock has trended positive on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 2.6 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the next several days.
Who are some of Alexion Pharmaceuticals' key competitors?
Some companies that are related to Alexion Pharmaceuticals include AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA) and UCB (UCBJF).
Who are Alexion Pharmaceuticals' key executives?
Alexion Pharmaceuticals' management team includes the folowing people:
- Dr. Ludwig N. Hantson, CEO & Director (Age 55)
- Mr. Paul J. Clancy, Exec. VP & CFO (Age 56)
- Mr. Brian Goff, Exec. VP & Chief Commercial Officer (Age 49)
- Mr. Daniel A. Bazarko CPA, Chief Accounting Officer & Sr. VP
- Ms. Indrani M. Lall Franchini, Exec. VP & Chief Compliance Officer (Age 46)
Who are Alexion Pharmaceuticals' major shareholders?
Alexion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (9.46%), BlackRock Inc. (7.31%), Vanguard Group Inc. (7.09%), Vanguard Group Inc (7.09%), Jennison Associates LLC (3.87%) and Clearbridge Investments LLC (2.32%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, Edward Miller, Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Leonard Bell, Ludwig Hantson and Paul J Clancy. View Institutional Ownership Trends for Alexion Pharmaceuticals.
Which institutional investors are selling Alexion Pharmaceuticals stock?
ALXN stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Banco Santander S.A., Bank of Montreal Can, Bank of New York Mellon Corp, AXA, Mitsubishi UFJ Trust & Banking Corp, Swedbank and Marshall Wace LLP. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Heidi L Wagner, Indrani Lall Franchini, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.
Which institutional investors are buying Alexion Pharmaceuticals stock?
ALXN stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, American Century Companies Inc., Iridian Asset Management LLC CT, Clearbridge Investments LLC, First Trust Advisors LP, Wells Fargo & Company MN and Point72 Asset Management L.P.. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.
How do I buy shares of Alexion Pharmaceuticals?
Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alexion Pharmaceuticals' stock price today?
One share of ALXN stock can currently be purchased for approximately $112.43.
How big of a company is Alexion Pharmaceuticals?
Alexion Pharmaceuticals has a market capitalization of $25.62 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.
What is Alexion Pharmaceuticals' official website?
How can I contact Alexion Pharmaceuticals?
Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]
MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
